Copyright
©The Author(s) 2016.
World J Gastroenterol. Jan 21, 2016; 22(3): 1311-1320
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1311
Published online Jan 21, 2016. doi: 10.3748/wjg.v22.i3.1311
1st line regimen | 2nd line regimen | |
Japan[15] | PPI, amoxicillin 750 mg, clarithromycin 200 mg to 400 mg twice daily | PPI, amoxicillin 750 mg, metronidazole 250 mg twice daily |
Duration: 7 d | Duration: 7 d | |
Korea[14] | PPI, amoxicillin 1 g, clarithromycin 500 mg twice daily | PPI, bismuth 120 mg four times daily, tetracycline 500 mg four times daily, metronidazole 500 mg three times daily |
Duration: 7-14 d | Duration: 7-14 d | |
Europe[16] | PPI-clarithromycin containing triple therapy OR | Bismuth-containing quadruple therapy OR levofloxacin-containing triple |
Bismuth or non-bismuth containing quadruple1 | ||
Duration: 7-14 d | Duration: 10 d | |
China[13] | No preferential choice. Options include: (1)PPI, amoxicillin 1 g, clarithromycin 500 mg twice daily (2) PPI, amoxicillin 1 g, levofloxacin 200 mg twice daily (or levofloxacin 500 mg daily) (3) PPI, amoxicillin 1 g, furazolidone 100 mg twice daily (4) PPI, tetracycline 750 mg, metronidazole 400 mg twice daily (or metronidazole 400 mg three times per day) (5) PPI, bismuth 220 mg plus any of the two antibiotics above twice daily | |
Duration: 7-14 d |
- Citation: Liu KSH, Wong IOL, Leung WK. Helicobacter pylori associated gastric intestinal metaplasia: Treatment and surveillance. World J Gastroenterol 2016; 22(3): 1311-1320
- URL: https://www.wjgnet.com/1007-9327/full/v22/i3/1311.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i3.1311